MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) saw a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 62,409 shares, a drop of 61.8% from the January 15th total of 163,195 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average trading volume of 328,523 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 328,523 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.9% of the company’s shares are sold short.

MetaVia Price Performance

Shares of NASDAQ MTVA opened at $1.70 on Wednesday. The company has a market cap of $3.74 million, a price-to-earnings ratio of -0.20 and a beta of 0.27. The stock’s 50-day moving average is $6.26 and its two-hundred day moving average is $8.08. MetaVia has a 1-year low of $1.63 and a 1-year high of $23.10.

Institutional Trading of MetaVia

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC grew its stake in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,386 shares of the company’s stock after buying an additional 18,506 shares during the period. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. 1.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on MTVA. Wall Street Zen cut MetaVia from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Finally, HC Wainwright lifted their price target on shares of MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $36.50.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.